Dr. Monica Avila, MD

Dr. Avila practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Avila's NPI, 1194143776, was assigned on April 1, 2014. Dr. Avila graduated from The University of New Mexico School of Medicine in 2014. Dr. Avila holds Florida license ME156518.

Dr. Avila's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Avila's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Avila is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Avila to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Avila practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Avila's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Avila is board certified in obstetrics & gynecology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Avila's licenses on file in 3 states: Florida, Texas and California.

Dmand AI lists abdominal adhesion surgery and hysterectomy among the conditions Dr. Avila treats.

CMS counts 42 Medicare patients who saw Dr. Avila in 2024. The largest group is 65 to 74, with 30 patients. 71% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Avila's median patient age at 60, with 99% women.

In 2024, Dr. Avila wrote 50 Medicare Part D claims for 25 patients. 92% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $82 in total drug cost. In 2018, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Avila for performance year 2024, reported as part of a group. Dr. Avila accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Avila, published from 2020 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Ovarian Neoplasms, Phosphatidylinositol 3-Kinases and Poly(ADP-ribose) Polymerase Inhibitors. Dr. Avila has published most often in Gynecol Oncol Rep. Dr. Avila's most frequent co-authors are Shannon Neville Westin, MD, Emily Moss Hinchcliff, MD and Melissa Maria Pham, MD.

Dmand AI links Dr. Avila to 4 clinical trials, 2 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Endometrial Neoplasms, Mesothelioma, Malignant and Oropharyngeal Neoplasms.

CMS Open Payments shows 14 general payments to Dr. Avila from 6 drug and device companies from 2023 to 2024. Speaker and faculty fees make up the largest share, 75% of the total. Ascendis Pharma, Inc. paid the most, $4,856.

Dmand AI lists 20 awards for Dr. Avila, most recently CIRRC Pilot Grant Recipient in 2025. Dr. Avila serves on Moffitt Cancer Center Credentialing Committee, NRG Cervical/Vulvar Disease Site and NRG Developmental Therapeutics Committee.

Dr. Avila graduated from The University of New Mexico School of Medicine in 2014. Dr. Avila is a member of American Society Clinical Oncology, ASCO, GOG, Hillsborough County Medical Association, International Papillomavirus Society and NRG.

Dr. Avila is in network with 7 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.